Sino-Singapore Online, May 13th (Chen Jing, Yuan Huiyun) A reporter learned on the 13th that Professor Zhai Bo, the director of the Department of Oncology Intervention at the Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, etc., jointly completed relevant research and took the lead in focusing on CAR T cells Treatment safety research. The results of Phase I clinical research on CAR-T cells targeting related genes for the treatment of hepatocellular carcinoma are "available": the safety and effectiveness of the treatment have obtained promising results.
It is reported that the research results were published online in the internationally renowned academic journal-Clinical Cancer Research "Clinical Oncology Research".
Liver cancer is one of the major diseases that seriously threaten the lives and health of Chinese people. In recent years, CAR-T cell therapy, as an emerging immunotherapy method, has become the focus and hotspot of global cancer therapy research. The clinical research results of CAR-T cells targeted to related genes for the treatment of hepatocellular carcinoma have not been reported before.
Zhai Bo told reporters that most patients are in the middle and late stages when they are diagnosed, and they may lose the chance of surgery. Although interventional treatment such as local ablation and hepatic artery embolization chemotherapy has brought new possibilities for the treatment of liver cancer patients who have lost the opportunity for surgery, patients with advanced liver cancer have a high rate of recurrence and metastasis, and more efficient and low-toxic systemic treatment methods must be continuously developed.
It is reported that the Chinese name of CAR-T is called "chimeric antigen receptor modified T lymphocytes". Zhai Bo explained to reporters that, simply speaking, T lymphocytes have immunological activity, just like the army in the human body, and are the main force to kill tumor cells. CAR is a kind of molecular modification. It is equipped with a navigation system that can specifically recognize tumor cells and other molecules involved in the immune response. It can carry T lymphocytes to accurately identify and eliminate tumor cells that express a certain gene. Damage the normal cells of the human body.
In 2015, led by Professor Zhai Bo, Renji Hospital cooperated with relevant biotechnology companies to take the lead in the clinical trial of CAR-T cells targeting GPC3 for the treatment of advanced hepatocellular carcinoma. It is reported that Li Zonghai, a researcher and doctoral supervisor of the National Key Laboratory of Oncogenes and Related Genes at the Shanghai Cancer Institute of Renji Hospital, told reporters that GPC3 is a carcinoembryonic antigen that participates in cell proliferation, differentiation, migration and apoptosis, and is considered to be Very promising target for tumor immunotherapy. It is understood that Li Zonghai has been engaged in tumor transformation research for a long time and is committed to the development of highly effective treatment and even cure drugs for tumors. He is one of the pioneers of CAR-T immune cells for the treatment of solid tumors,
It is reported that after receiving CAR-T cell therapy with GPC3 as the target, the patient is well tolerated, safe and basically controllable, with severe serious side effects and rare, and initially shows good clinical benefits. Among them, a patient with advanced liver cancer treated with CAR-T survived for nearly 5 years without tumor, and no active lesions were found during regular review. The tumor markers were normal. This patient was officially enrolled in July 2015. Related CAR-T Cell therapy.
Zhai Bo pointed out that the research still has a lot to be improved, and there is still a long way to go in the future, but this has accumulated valuable experience for CAR-T cells to treat various solid tumors such as hepatocellular carcinoma, and also shows that CAR- T cells may indeed bring long-term benefits to some liver cancer patients. (Finish)